Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Onychomycosis (Tinea Unguium) Overview 8 Therapeutics Development 9 Pipeline Products for Onychomycosis (Tinea Unguium) - Overview 9 Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis 10 Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies 11 Onychomycosis (Tinea Unguium) - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Onychomycosis (Tinea Unguium) - Products under Development by Companies 16 Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development 17 Almirall, S.A. 17 Anacor Pharmaceuticals, Inc. 18 Arno Therapeutics, Inc. 19 Blueberry Therapeutics Ltd 20 Crescita Therapeutics Inc. 21 Eisai Co., Ltd. 22 Helix BioMedix, Inc. 23 Hexima Limited 24 Meiji Seika Pharma Co., Ltd. 25 Moberg Pharma AB 26 NAL Pharmaceuticals Ltd. 27 Nihon Nohyaku Co., Ltd. 28 Novabiotics Limited 29 Novan, Inc. 30 Viamet Pharmaceuticals, Inc. 31 Onychomycosis (Tinea Unguium) - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 AN-2718 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 AR-12 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 BB-0305 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Drug for Onychomycosis - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 ELS-160 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 fosravuconazole - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 HB-1275 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 HXP-124 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 luliconazole - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 ME-1111 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 NAL-3216 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 NP-213 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 SB-208 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 terbinafine - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 terbinafine - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 terbinafine - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 VT-1161 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Onychomycosis (Tinea Unguium) - Dormant Projects 68 Onychomycosis (Tinea Unguium) - Discontinued Products 71 Onychomycosis (Tinea Unguium) - Product Development Milestones 72 Featured News & Press Releases 72 May 18, 2016: Moberg Pharma Announces Multiple Patent Approvals for MOB-015 72 Mar 02, 2016: Viamet Reports Positive Results from Interim Analysis of RENOVATE Phase 2b Trial of VT-1161 in Onychomycosis 72 Jan 21, 2016: Moberg Pharma is contemplating a potential bond issue, updates financial targets and provides update on MOB-015 73 Jan 07, 2016: Viamet to Present at the 3rd Annual Dermatology Summit 74 Aug 11, 2015: Nuvo Research Announces Grant of United States Patent for Topical Onychomycosis Formulation 74 Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting 75 Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus) 75 Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology 76 Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis 76 Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis 77 Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis 77 Sep 10, 2014: Data for Viamet’s VT-1161 Presented at ICAAC 2014 78 Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015 78 May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015 79 Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis 79 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 80 Disclaimer 81

List of Tables Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2016 9 Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Comparative Analysis by Unknown Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Onychomycosis (Tinea Unguium) - Pipeline by Almirall, S.A., H2 2016 17 Onychomycosis (Tinea Unguium) - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 18 Onychomycosis (Tinea Unguium) - Pipeline by Arno Therapeutics, Inc., H2 2016 19 Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H2 2016 20 Onychomycosis (Tinea Unguium) - Pipeline by Crescita Therapeutics Inc., H2 2016 21 Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co., Ltd., H2 2016 22 Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix, Inc., H2 2016 23 Onychomycosis (Tinea Unguium) - Pipeline by Hexima Limited, H2 2016 24 Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2016 25 Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H2 2016 26 Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd., H2 2016 27 Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co., Ltd., H2 2016 28 Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Limited, H2 2016 29 Onychomycosis (Tinea Unguium) - Pipeline by Novan, Inc., H2 2016 30 Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016 31 Assessment by Monotherapy Products, H2 2016 32 Number of Products by Stage and Target, H2 2016 34 Number of Products by Stage and Mechanism of Action, H2 2016 36 Number of Products by Stage and Route of Administration, H2 2016 38 Number of Products by Stage and Molecule Type, H2 2016 40 Onychomycosis (Tinea Unguium) - Dormant Projects, H2 2016 68 Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..1), H2 2016 69 Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..2), H2 2016 70 Onychomycosis (Tinea Unguium) - Discontinued Products, H2 2016 71 List of Figures Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2016 9 Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 14 Assessment by Monotherapy Products, H2 2016 32 Number of Products by Top 10 Targets, H2 2016 33 Number of Products by Stage and Top 10 Targets, H2 2016 33 Number of Products by Top 10 Mechanism of Actions, H2 2016 35 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 35 Number of Products by Routes of Administration, H2 2016 37 Number of Products by Stage and Routes of Administration, H2 2016 37 Number of Products by Molecule Types, H2 2016 39 Number of Products by Stage and Molecule Types, H2 2016 39

Almirall, S.A. Anacor Pharmaceuticals, Inc. Arno Therapeutics, Inc. Blueberry Therapeutics Ltd Crescita Therapeutics Inc. Eisai Co., Ltd. Helix BioMedix, Inc. Hexima Limited Meiji Seika Pharma Co., Ltd. Moberg Pharma AB NAL Pharmaceuticals Ltd. Nihon Nohyaku Co., Ltd. Novabiotics Limited Novan, Inc. Viamet Pharmaceuticals, Inc.